49,294
edits
Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
Prostate-specific antigen (view source)
Revision as of 16:09, 21 September 2025
, 16:09, 21 September 2025→Free serum PSA/total PSA
| (12 intermediate revisions by 2 users not shown) | |||
| Line 7: | Line 7: | ||
===Serum PSA=== | ===Serum PSA=== | ||
*Normal - typically <= 4.0 ng/ | *Normal - typically <= 4.0 ng/ml. | ||
**[[Sensitivity]]: 82% (whites), 90% (blacks).<ref name=pmid8998182>{{Cite journal | last1 = Henderson | first1 = RJ. | last2 = Eastham | first2 = JA. | last3 = Culkin | first3 = DJ. | last4 = Kattan | first4 = MW. | last5 = Whatley | first5 = T. | last6 = Mata | first6 = J. | last7 = Venable | first7 = D. | last8 = Sartor | first8 = O. | title = Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. | journal = J Natl Cancer Inst | volume = 89 | issue = 2 | pages = 134-8 | month = Jan | year = 1997 | doi = | PMID = 8998182 }} | **[[Sensitivity]]: 82% (whites), 90% (blacks).<ref name=pmid8998182>{{Cite journal | last1 = Henderson | first1 = RJ. | last2 = Eastham | first2 = JA. | last3 = Culkin | first3 = DJ. | last4 = Kattan | first4 = MW. | last5 = Whatley | first5 = T. | last6 = Mata | first6 = J. | last7 = Venable | first7 = D. | last8 = Sartor | first8 = O. | title = Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. | journal = J Natl Cancer Inst | volume = 89 | issue = 2 | pages = 134-8 | month = Jan | year = 1997 | doi = | PMID = 8998182 }} | ||
</ref> | </ref> | ||
| Line 14: | Line 14: | ||
Age-normal: | Age-normal: | ||
*40s - 2.5. | *40s - 2.5 ng/ml. | ||
*50s - 3.5. | *50s - 3.5 ng/ml. | ||
*60s - 4.5. | *60s - 4.5 ng/ml. | ||
*70s - 6.5. | *70s - 6.5 ng/ml. | ||
Note: | |||
*The units for PSA may also be μg/L; note that 1 μg/L = 1 ng/ml. | |||
====Prostate-specific antigen density==== | ====Prostate-specific antigen density==== | ||
:Abbreviated ''PSAD''. | :Abbreviated ''PSAD''. | ||
Normal is often considered to be: <0.15 ng/ml. | Normal is often considered to be: <0.15 ng/ml<sup>2</sup>. | ||
*Approximately 8% of individuals below the cut-point (0.15 ng/ml) have medium or high-grade cancer.<ref name=pmid12973074>{{Cite journal | last1 = Boulos | first1 = MT. | last2 = Rifkin | first2 = MD. | last3 = Ross | first3 = J. | title = Should prostate-specific antigen or prostate-specific antigen density be used as the determining factor when deciding which prostates should undergo biopsy during prostate ultrasound. | journal = Ultrasound Q | volume = 17 | issue = 3 | pages = 177-80 | month = Sep | year = 2001 | doi = | PMID = 12973074 }} | *Approximately 8% of individuals below the cut-point (0.15 ng/ml) have medium or high-grade cancer.<ref name=pmid12973074>{{Cite journal | last1 = Boulos | first1 = MT. | last2 = Rifkin | first2 = MD. | last3 = Ross | first3 = J. | title = Should prostate-specific antigen or prostate-specific antigen density be used as the determining factor when deciding which prostates should undergo biopsy during prostate ultrasound. | journal = Ultrasound Q | volume = 17 | issue = 3 | pages = 177-80 | month = Sep | year = 2001 | doi = | PMID = 12973074 }} | ||
</ref> | </ref> | ||
*In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml.<ref name=pmid22482342>{{Cite journal | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month = | year = 2012 | doi = | PMID = 22482342 }} | *In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml<sup>2</sup>.<ref name=pmid22482342>{{Cite journal | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month = | year = 2012 | doi = | PMID = 22482342 }} | ||
</ref> | </ref> | ||
*Differences between races have been noted in one study; in those without prostate cancer:<ref name=pmid8998182/> | *Differences between races have been noted in one study; in those without prostate cancer:<ref name=pmid8998182/> | ||
**0.19 +/- 0.03 ng/ml (blacks). | **0.19 +/- 0.03 ng/ml<sup>2</sup> (blacks). | ||
**0.11 +/- 0.01 ng/ml (whites). | **0.11 +/- 0.01 ng/ml<sup>2</sup> (whites). | ||
PSAD is a better predictor than (unadjusted) serum PSA for: | PSAD is a better predictor than (unadjusted) serum PSA for: | ||
| Line 47: | Line 51: | ||
:D1, D2, D3 are the major axes. | :D1, D2, D3 are the major axes. | ||
Notes: | |||
*The volume of an ellipsoid is: | *The volume of an ellipsoid is: | ||
::<math>\frac{4}{3}\pi D1 \times D1 \times D3</math>. | ::<math>\frac{4}{3}\pi D1 \times D1 \times D3</math>. | ||
*As 1 cm<sup>3</sup> is equal to 1 ml, the units of PSAD are (ng/ml)/cm<sup>3</sup> or ng/ml<sup>2</sup>. | |||
====Free serum PSA/total PSA==== | |||
:Also ''PSA free-to-total ratio'' (abbreviated ''FTR''<ref name=pmid39607059>{{cite journal |authors=Sii S, Papa N, Yiu TW, Tempo J, Qu L, Perera M, Thompson I, Ischia J, Fleshner N, Smith E, Ranasinghe W, Bolton D, Woon DT |title=Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL |journal=BJU Int |volume=135 |issue=4 |pages=550–556 |date=April 2025 |pmid=39607059 |doi=10.1111/bju.16597 |url=}}</ref>) and ''PSA free/PSA ratio'' | |||
* PSA in the serum can be found bound to protein or unbound (free).<ref>{{cite journal |authors=Cazanave Mora JM, Del Valle García R, Pérez López L, Bequer Ariza DC, Zulueta Rodríguez O, Melchor Rodríguez A, Hernández Pérez L, López Cisneros R, Arteaga Yera AL, Silva Cabrera E, Fernández Yero JL |title=Measurement of total and free prostate specific antigen (PSA) in human serum samples using an ultra-microanalytical system |journal=J Pharm Biomed Anal |volume=208 |issue= |pages=114470 |date=January 2022 |pmid=34798395 |doi=10.1016/j.jpba.2021.114470 |url=}}</ref> | |||
* High values of FTR have a lower risk of prostate cancer. | |||
** Modelling based on a cohort 406 men showed that: FTR ≤0.15 ~46% had prostate cancer versus FTR ≥0.20 ~22% had prostate cancer.<ref name=pmid39607059/> | |||
===Phoenix definition of biochemical failure=== | |||
Failure after radiotherapy: | |||
*PSA nadir + 2 ug/L.<ref name=pmid17968996>{{cite journal |authors=Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM |title=The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer |journal=Cancer |volume=112 |issue=1 |pages=55–60 |date=January 2008 |pmid=17968996 |doi=10.1002/cncr.23139 |url=}}</ref> | |||
===Immunostain=== | ===Immunostain=== | ||
* | *Relatively specific for prostate | ||
*May be found in normal pancreatic, salivary gland, Skene's glands and lactating breast tissue.<ref name=pmid21979599>{{cite journal |authors=Kelly P, McBride HA, Kennedy K, Connolly LE, McCluggage WG |title=Misplaced Skene's glands: glandular elements in the lower female genital tract that are variably immunoreactive with prostate markers and that encompass vaginal tubulosquamous polyp and cervical ectopic prostatic tissue |journal=Int. J. Gynecol. Pathol. |volume=30 |issue=6 |pages=605–12 |date=November 2011 |pmid=21979599 |doi=10.1097/PGP.0b013e31821713b6 |url=}}</ref> | |||
*In women, positive in up to 30-40% of breast cancers and also in tubulo-squamous polyps of the vagina. | |||
==Microscopic== | ==Microscopic== | ||
| Line 71: | Line 88: | ||
*[[Prostate cancer]]. | *[[Prostate cancer]]. | ||
*[[Prostatic-specific acid phosphatase]]. | *[[Prostatic-specific acid phosphatase]]. | ||
*[[NKX3.1]]. | |||
==References== | ==References== | ||